Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
Sanjay Singh Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0fddc80cf1e046f99472a75fe1b0011d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Sanjay Singh Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Keywords: drug delivery, nanoliposomes, nanomedicines, cancer nanotechnology |
|---|